ATE9062T1 - Zusammensetzung fuer die therapeutische oder diagnostische verwendung. - Google Patents

Zusammensetzung fuer die therapeutische oder diagnostische verwendung.

Info

Publication number
ATE9062T1
ATE9062T1 AT81850035T AT81850035T ATE9062T1 AT E9062 T1 ATE9062 T1 AT E9062T1 AT 81850035 T AT81850035 T AT 81850035T AT 81850035 T AT81850035 T AT 81850035T AT E9062 T1 ATE9062 T1 AT E9062T1
Authority
AT
Austria
Prior art keywords
structural element
composition
mammals including
including man
therapeutic
Prior art date
Application number
AT81850035T
Other languages
English (en)
Inventor
Gunilla Petterson Kaellenius
Karl Arne Lundblad
Nils Roland Moellby
Stefan Birger Svensson
Jan Winberg
Original Assignee
Gunilla Petterson Kaellenius
Karl Arne Lundblad
Nils Roland Moellby
Stefan Birger Svensson
Jan Winberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gunilla Petterson Kaellenius, Karl Arne Lundblad, Nils Roland Moellby, Stefan Birger Svensson, Jan Winberg filed Critical Gunilla Petterson Kaellenius
Application granted granted Critical
Publication of ATE9062T1 publication Critical patent/ATE9062T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT81850035T 1980-03-05 1981-03-05 Zusammensetzung fuer die therapeutische oder diagnostische verwendung. ATE9062T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8001748A SE8001748L (sv) 1980-03-05 1980-03-05 Kompositioner for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutik
EP81850035A EP0035484B1 (de) 1980-03-05 1981-03-05 Zusammensetzung für die therapeutische oder diagnostische Verwendung

Publications (1)

Publication Number Publication Date
ATE9062T1 true ATE9062T1 (de) 1984-09-15

Family

ID=20340427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT81850035T ATE9062T1 (de) 1980-03-05 1981-03-05 Zusammensetzung fuer die therapeutische oder diagnostische verwendung.

Country Status (10)

Country Link
US (2) US4657849A (de)
EP (1) EP0035484B1 (de)
JP (1) JPH0322397B2 (de)
AT (1) ATE9062T1 (de)
AU (1) AU546148B2 (de)
DE (1) DE3165623D1 (de)
DK (2) DK489581A (de)
FI (1) FI71432C (de)
SE (1) SE8001748L (de)
WO (1) WO1981002520A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464360A (en) * 1980-05-09 1984-08-07 Hakon Leffler Glycosphingalipids for inhibiting bacterial adherence
US4521592A (en) * 1981-10-23 1985-06-04 Svenska Sockerfabriks Ab Compounds for therapeutic or diagnostic use, a process and intermediates for their preparation
AU561066B2 (en) * 1982-03-22 1987-04-30 Biocarb Ab Antibacterial composition containing an oligosaccharide
AU561067B2 (en) * 1982-03-22 1987-04-30 Biocarb Ab Anti-bacterial composition containing an oligosaccharide
DK131083A (da) * 1982-03-23 1983-09-24 Svenska Sockerfabriks Ab Fremgangsmaade til fremstilling af terapeutiske eller diagnostiske praeparater
SE8301609D0 (sv) * 1983-03-23 1983-03-23 Svenska Sockerfabriks Ab Forening och komposition for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutisk behandling
SE8304006D0 (sv) * 1983-07-15 1983-07-15 Karlsson Karl Anders Forening och komposition for terapeutisk eller diagnostisk anvendning samt forfarande for terapeutisk behandling
SE8304007D0 (sv) * 1983-07-15 1983-07-15 Karlsson Karl Anders Forening och komposition for terapeutisk eller diagnostisk anvendning samt forfarande for terapeutisk behandling
DE3402739A1 (de) * 1984-01-27 1985-08-01 Boehringer Ingelheim Diagnostika GmbH, 8046 Garching Antikoerper gegen den glycanstrang des peptidoglycans, verfahren und reagenzien zu ihrer herstellung und methoden zu ihrer quantitativen bestimmung
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
SE8406626D0 (sv) * 1984-12-27 1984-12-27 Bio Carb Ab Forening och komposition for terapeutisk eller diagnostisk anvendning jemte anvendning av sadan forening och komposition for terapeutisk behandling och isolering av shigatoxin
IL76981A (en) * 1985-11-07 1989-02-28 Univ Ramot Bacterially produced hetero polysaccharide dispersants for inorganic minerals in aqueous medium and their preparation
US5324828A (en) * 1986-12-11 1994-06-28 Genzyme Corporation 1-amino-1-deoxyoligosaccharides and derivatives thereof
US4857639A (en) * 1987-01-12 1989-08-15 The Biomembrane Institute A-associated H-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing
US4942224A (en) * 1987-01-12 1990-07-17 The Biomembrane Institute A-associated H-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing
US5112770A (en) * 1988-06-08 1992-05-12 North Carolina State University Precipitation of multivalent antiligands with affinity surfactants
US5167925A (en) * 1988-06-08 1992-12-01 North Carolina State University Precipitation of multivalent antiligands with affinity surfactants
US5164298A (en) * 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
DK455088D0 (da) * 1988-08-12 1988-08-12 Symbicom Ab Syntetiske receptoranaloger
WO1991008747A1 (en) * 1989-12-13 1991-06-27 Glycomed Incorporated Synthetic receptor molecules recognizable by a rotavirus
AU7153991A (en) * 1989-12-13 1991-07-18 Glycomed Incorporated Synthesis of rotavirus receptor saccharides
US5466681A (en) * 1990-02-23 1995-11-14 Microcarb, Inc. Receptor conjugates for targeting penicillin antibiotics to bacteria
EP0553113B1 (de) * 1990-08-02 1998-11-25 Antex Biologics, Inc. Adhäsionsrezeptoren für pathogene oder opportunistische mikroorganismen
SE9003222L (sv) * 1990-10-10 1992-04-11 Jens Sandros Preparat foer profylaktiskt,terapeutiskt och diagnostiskt bruk vid infektioner
FR2671100B1 (fr) * 1990-12-28 1993-03-05 Bio Merieux Procede d'analyse bacteriologique, et milieu de detection des bacteries genre salmonella.
ES2150888T1 (es) * 1991-10-18 2000-12-16 Synsorb Biotech Inc Diagnosis y tratamiento de la disenteria bacteriana.
JPH09501044A (ja) * 1993-05-14 1997-02-04 ジ・アップジョン・カンパニー ＵＤＰ−ＧＡＬＮＡｃ：ポリペプチド、Ｎ−アセチルガラクトサミニルトランスフェラーゼをコードするクローン化されたＤＮＡ
US5910570A (en) * 1995-11-13 1999-06-08 Pharmacia & Upjohn Company Cloned DNA encoding a UDP-GalNAc: polypeptide N-acetylgalactosaminy-ltransferase
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
DE69927369T2 (de) * 1998-04-15 2006-06-22 Mayo Foundation For Medical Education And Research, Rochester Hemmung xenoreaktiver antikörper
JP3772204B2 (ja) * 2000-06-05 2006-05-10 独立行政法人産業技術総合研究所 糖鎖誘導体及びその製造方法
US7238677B2 (en) * 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
US20050095219A1 (en) * 2003-10-29 2005-05-05 Shu-Ping Yang Compositions for promoting vaginal cell proliferation and maturation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1910715A1 (de) * 1968-03-04 1969-10-09 Stanley Drug Products Inc Antimikrobielle Faktoren und deren Verwendung
US4125492A (en) * 1974-05-31 1978-11-14 Pedro Cuatrecasas Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers
GB1544908A (en) * 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
FR2422681A1 (fr) * 1978-04-10 1979-11-09 Anvar Procede de preparation de derives d'osides, les nouveaux derives d'osides obtenus et leurs applications biologiques

Also Published As

Publication number Publication date
FI71432C (fi) 1986-12-19
AU546148B2 (en) 1985-08-15
FI814230L (fi) 1981-12-31
AU6779581A (en) 1981-09-23
US4762824A (en) 1988-08-09
DK489581A (da) 1981-11-04
EP0035484A3 (en) 1981-09-16
DE3165623D1 (en) 1984-09-27
EP0035484B1 (de) 1984-08-22
US4657849A (en) 1987-04-14
WO1981002520A1 (en) 1981-09-17
JPH0322397B2 (de) 1991-03-26
FI71432B (fi) 1986-09-09
SE8001748L (sv) 1981-09-06
JPS57500194A (de) 1982-02-04
DK75787D0 (da) 1987-02-13
DK75787A (da) 1987-02-13
EP0035484A2 (de) 1981-09-09

Similar Documents

Publication Publication Date Title
ATE9062T1 (de) Zusammensetzung fuer die therapeutische oder diagnostische verwendung.
DK609985A (da) Adhesin-antigener, antistoffer mod disse og dna-fragmenter, som indkoder antigenerne
DE3070803D1 (en) Monoclonal-antibody-producing hybrid cell line, antibody and method of preparing it, therapeutic composition containing it and its diagnostic and therapeutic uses
DK154087C (da) Monoklonalt antistof, fremstilling heraf, hybrodimacellelinie til anvendelse ved fremstilling heraf, fremgangsmaade til anvendelse heraf samt diagnostisk praeparat indeholdende antistoffet
ATE245699T1 (de) Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie
ATE13198T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellenantigen, antikoerper und verfahren.
DE69333802D1 (de) Äusseres membranprotein von haemophilus
ATE14233T1 (de) Monoklonaler antikoerper gegen menschliche tzellen, verfahren zu seiner herstellung, ihn produzierende hybridzellinie, ihn enthaltende therapeutische zusammensetzung und ihn verwendendes diagnostisches verfahren.
DE69032979D1 (de) Bispezifische heteroantikörper mit zweifachen effektorfunktionen
DK346783D0 (da) Triphenylimidazolyloxyalkansyrer og derivater deraf, fremgangsmade til fremstilling deraf og farmaceutiske praeparater indeholdende disse forbindelser
ATE16406T1 (de) Verfahren zur herstellung von isomaltulose (6-o- alpha-d-gluco-pyranosido-d-fructose) mit hilfe von immobilisierten bakterienzellen.
DE3582373D1 (de) Herstellung des e.coli-lt-b-enterotoxinunterteils.
EP0918865A1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
PT74470B (de) Chemische verbindungen verfahren zu ihrer herstellung und ihre verwendungen als antigene oder immunadsorbentien
Drucker et al. Electrophoretic and immunological differences between the cytochrome c 3 of Desulfovibrio desulfuricans and that of Desulfovibrio vulgaris
Koyata et al. Purification and characterization of a fimbrial protein from Porphyromonas salivosa ATCC 49407
Seligmann et al. Immunological Studies in Familial β 2-Macroglobulinaemias.
DE4400990A1 (de) Antikörper für den Nachweis von Salmonellen
EP0101886A3 (de) Antikörper gegen bakterielle Peptidoglycane, Verfahren zu ihrer Herstellung und Methoden zu ihrer quantitativen Bestimmung
DE69232140D1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
ATE7700T1 (de) 2-hydroxy-1,2,4-butantricarbonsaeure-oligoribosi - derivate, verfahren zu ihrer herstellung und ihre verwendung als prophylaktische mittel gegen zahnkaries.
Castermans et al. Transplantation immunity: separation of antigenic components from isolated nuclei
Gilot et al. Mycobacterium paratuberculosis and Escherichia coli share common antigenic determinants
ATE17083T1 (de) Entgiftetes nervengift aus e-coli, verfahren zu dessen herstellung und dasselbe enthaltende immunologische zusammensetzungen.
Bragg Characterization of fimbriae of Actinomyces naeslundii N16 using monoclonal and polyclonal antibodies

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee